Breaking News Instant updates and real-time market news.

BLCM

Bellicum Pharmaceuticals

$6.85

0.1 (1.48%)

05:41
04/12/18
04/12
05:41
04/12/18
05:41

Wells Fargo upgrades Bellicum to Outperform on lifting of clinical hold

Wells Fargo analyst Jim Birchenough last night upgraded Bellicum Pharmaceuticals to Outperform from Market Perform and raised his price target for the shares to $23 from $6. The shares in premarket trading are up 27% to $8.70 following news that the FDA lifted the clinical hold on studies of BPX-501 in the U.S. Rapid resolution of the clinical hold "substantially de-risks the investment," Birchenough tells investors in a research note. He believes Bellicum's platform for controllable cell therapies is well positioned for therapeutic oncology indications.

BLCM Bellicum Pharmaceuticals
$6.85

0.1 (1.48%)

04/11/18
WELS
04/11/18
UPGRADE
WELS
Outperform
Bellicum Pharmaceuticals upgraded to Outperform at Wells Fargo
03/14/18
JEFF
03/14/18
NO CHANGE
Target $16
JEFF
Buy
Bellicum clinical hold should lift soon, says Jefferies
Jefferies analyst Biren Amin says Bellicum Pharmaceuticals last night provided an update of its leading prgm BPX-501 with an "encouraging" survival rate at one year in pediatric acute myeloid leukemia patients. For BPX-601, management reported CART cell expansion in one pancreatic cancer patient following rimiducid administration, providing first patient validation of the company's activation switch, Amin tells investors in a post-earnings research note. The analyst notes Bellicum has also responded to FDA including proposed protocol changes. Amin believes the clinical hold should lift soon and keeps a Buy rating on Bellicum Pharmaceuticals with a $16 price target.
02/26/18
JEFF
02/26/18
NO CHANGE
Target $16
JEFF
Buy
Bellicum should solve clinical hold within two months, says Jefferies
After hosting an investor meeting with Bellicum Pharmaceuticals management, Jefferies analyst Biren Amin thinks the FDA hold on BPX-501 should be solved in one to two months. To provide more details to FDA, Bellicum performed safety analysis in a database of BPX-501 and screened all patients for encephalopathy events, Amin tells investors in a research note. Seven cases were found in 241 treated patients, resulting a 2.9% incidence rate, which is at the lower end of the background rate associated with allo-transplant, the analyst points out. Amin points out that based on its analysis, management believes BPX-501 associated encephalopathy events show no similarities with acute and detrimental CD19-CART therapy related neurotoxicity. Bellicum expects to provide a full response to FDA in March, the analyst notes. Amin keeps a Buy rating on the shares with a $16 price target.
02/16/18
SBSH
02/16/18
NO CHANGE
Target $27
SBSH
Buy
Citi sees Bellicum shares recovering, ups price target to $27
Citi analyst Robyn Karnauskas raised her price target for Bellicum Pharmaceuticals to $27 from $24 following a meeting with management. In a research note titled "Missed CAR-T? We have another story for you. New TP $27," the analyst says she believes the stock can recover after declining 27% following the patient death and clinical hold announced on January 30. Other CAR-T companies' stock prices have recovered after clinical holds have been lifted, Karnauskas tells investors in a research note. She believes a partnership could serve as a catalyst for the stock in 2018 or 2019. The analyst keeps a Buy rating on Bellicum Pharmaceuticals.

TODAY'S FREE FLY STORIES

GPS

Gap

$28.28

-1.275 (-4.31%)

14:35
04/20/18
04/20
14:35
04/20/18
14:35
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$84.12

-1.53 (-1.79%)

14:33
04/20/18
04/20
14:33
04/20/18
14:33
Conference/Events
Philip Morris management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ALXN

Alexion

$105.99

-5.75 (-5.15%)

14:30
04/20/18
04/20
14:30
04/20/18
14:30
Recommendations
Alexion analyst commentary  »

Brazilian generic risk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

14:30
04/20/18
04/20
14:30
04/20/18
14:30
General news
Action Economics Survey results »

Action Economics Survey…

UCBI

United Community Banks

$32.40

0.27 (0.84%)

14:29
04/20/18
04/20
14:29
04/20/18
14:29
Syndicate
Breaking Syndicate news story on United Community Banks »

United Community Banks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

HRTX

Heron Therapeutics

$30.40

0.6 (2.01%)

14:24
04/20/18
04/20
14:24
04/20/18
14:24
Recommendations
Heron Therapeutics analyst commentary  »

Helsinn CINV product no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TGI

Triumph Group

$26.05

-0.2 (-0.76%)

14:20
04/20/18
04/20
14:20
04/20/18
14:20
Options
Put buying in Triumph Group »

Put buying in Triumph…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
04/20/18
04/20
14:17
04/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
04/20/18
04/20
14:16
04/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$31.93

0.39 (1.24%)

14:14
04/20/18
04/20
14:14
04/20/18
14:14
Periodicals
Twitter bans ads from Kaspersky Lab, Reuters reports »

Twitter said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.73

0.74 (5.29%)

, WAB

Wabtec

$88.35

4.61 (5.51%)

14:07
04/20/18
04/20
14:07
04/20/18
14:07
Periodicals
GE explores merging transport unit with Wabtec, Reuters says »

GE (GE) is looking into…

GE

General Electric

$14.73

0.74 (5.29%)

WAB

Wabtec

$88.35

4.61 (5.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 24

    Apr

  • 25

    Apr

  • 15

    May

  • 12

    Jun

KMB

Kimberly-Clark

$99.75

-3.59 (-3.47%)

14:05
04/20/18
04/20
14:05
04/20/18
14:05
Technical Analysis
Technical Earnings Preview: Kimberly-Clark near 5-year lows ahead of earnings »

The shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 30

    May

DVMT

Dell Technologies

$73.08

-0.81 (-1.10%)

14:05
04/20/18
04/20
14:05
04/20/18
14:05
Options
Dell Technologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

WEN

Wendy's

$17.23

-0.165 (-0.95%)

14:02
04/20/18
04/20
14:02
04/20/18
14:02
Hot Stocks
Wendy's announces 2020 goal of opening over 600 new restaurants globally »

The Wendy's Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 30

    May

14:00
04/20/18
04/20
14:00
04/20/18
14:00
General news
Fed Governor Brainard did not break from the gradualist mantra »

Fed Governor Brainard did…

LITE

Lumentum

$59.70

-0.25 (-0.42%)

13:55
04/20/18
04/20
13:55
04/20/18
13:55
Options
Lumentum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 29

    May

ALXN

Alexion

$104.44

-7.3 (-6.53%)

13:46
04/20/18
04/20
13:46
04/20/18
13:46
Hot Stocks
Alexion drops after Brazil AG says Soliris patent made public »

Shares of Alexion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AKRX

Akorn

$19.61

0.24 (1.24%)

13:45
04/20/18
04/20
13:45
04/20/18
13:45
Options
Akorn call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
04/20/18
04/20
13:45
04/20/18
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY topped…

TGT

Target

$70.52

-0.45 (-0.63%)

13:35
04/20/18
04/20
13:35
04/20/18
13:35
Options
Target put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

IWM

iShares Trust Russell 2000 Index Fund

$155.75

-0.65 (-0.42%)

, RUT

Russell 2000 Index

13:35
04/20/18
04/20
13:35
04/20/18
13:35
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

At time of writing, the…

IWM

iShares Trust Russell 2000 Index Fund

$155.75

-0.65 (-0.42%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$50.43

-0.915 (-1.78%)

, XLRE

Real Estate SPDR

$30.25

-0.25 (-0.82%)

13:33
04/20/18
04/20
13:33
04/20/18
13:33
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

For the last five days,…

XLP

Consumer Staples Sector SPDR

$50.43

-0.915 (-1.78%)

XLRE

Real Estate SPDR

$30.25

-0.25 (-0.82%)

XLK

Technology Select Sector SPDR

$66.26

-0.89 (-1.33%)

XLE

Energy Select Sector SPDR

$73.29

-0.37 (-0.50%)

XLB

S&P Select Materials SPDR

$58.95

-0.41 (-0.69%)

XLF

Financial Select Sector

$27.94

0.065 (0.23%)

SPY

SPDR S&P 500 ETF Trust

$266.75

-2.09 (-0.78%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$50.25

0.5 (1.01%)

13:25
04/20/18
04/20
13:25
04/20/18
13:25
Options
Scientific Games call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ALXN

Alexion

$110.26

-1.48 (-1.32%)

13:21
04/20/18
04/20
13:21
04/20/18
13:21
Periodicals
Brazil can produce generic Soliris after breaking Alexion patent, Bloomberg says »

Brazil's Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

WAB

Wabtec

$82.74

-1 (-1.19%)

, GE

General Electric

$14.46

0.47 (3.36%)

13:18
04/20/18
04/20
13:18
04/20/18
13:18
Hot Stocks
Wabtec rises after report of talks for GE rail business deal »

Shares of Wabtec (WAB)…

WAB

Wabtec

$82.74

-1 (-1.19%)

GE

General Electric

$14.46

0.47 (3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 24

    Apr

  • 25

    Apr

  • 15

    May

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.